Purple Biotech Ltd

NasdaqCM:PPBT Stock Report

Market Cap: US$7.0m

Purple Biotech Management

Management criteria checks 3/4

Purple Biotech's CEO is Gil Efron, appointed in Jul 2022, has a tenure of 2.25 years. total yearly compensation is $1.04M, comprised of 29.6% salary and 70.4% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $28.15K. The average tenure of the management team and the board of directors is 3.2 years and 3.5 years respectively.

Key information

Gil Efron

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage29.6%
CEO tenure2.3yrs
CEO ownership0.4%
Management average tenure3.2yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Purple Biotech GAAP EPS of $0.61

Aug 04

Purple Biotech CEO steps down, internal executive appointed for new role

Jul 14

Purple Biotech presents new clinical data from NT219 at ASCO annual meeting

Jun 04

Momentum Has Fallen Since June For Kitov Pharma, Future Upside Unlikely

Nov 02

CEO Compensation Analysis

How has Gil Efron's remuneration changed compared to Purple Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$308k

-US$20m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$365k

-US$22m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$357k

-US$18m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$758kUS$266k

-US$29m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$579kUS$263k

-US$5m

Compensation vs Market: Gil's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD657.80K).

Compensation vs Earnings: Gil's compensation has been consistent with company performance over the past year.

CEO

Gil Efron (58 yo)

2.3yrs

Tenure

US$1,040,342

Compensation

Mr. Gil Efron, CPA, M.A., serves as Chief Executive Officer of Purple Biotech Ltd. since July 10, 2022. He served as Chief Financial Officer at Purple Biotech Ltd.(formerly known as Kitov Pharma Ltd) sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Gil Efron
Chief Executive Officer2.3yrsUS$1.04m0.40%
$ 28.1k
Michael Schickler
Head of Clinical & Regulatory Affairs4.8yrsUS$482.37kno data
Lior Fhima
Chief Financial Officer1.9yrsno datano data
Ido Morpurgo
Vice President of Operations4.2yrsno datano data

3.2yrs

Average Tenure

55yo

Average Age

Experienced Management: PPBT's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yael Margolin
Independent Directorless than a yearno datano data
Simcha Rock
Independent Director11.3yrsUS$358.66kno data
Eric Rowinsky
Independent Chairman of the Board5yrsno datano data
Ido Agmon
Independent Director8.3yrsno datano data
Robert Gagnon
Independent Director3.6yrsno datano data
Eyal Gottlieb
Member of Scientific Advisory Board1.5yrsno datano data
Suzana Nahum-Zilberberg
Independent Director3.4yrsno datano data
Isaac Israel
Director12yrsUS$381.79kno data
Sunil Sharma
Member of Scientific Advisory Board1.5yrsno datano data
Steven Maron
Member of Scientific Advisory Board1.5yrsno datano data

3.5yrs

Average Tenure

53yo

Average Age

Experienced Board: PPBT's board of directors are considered experienced (3.5 years average tenure).